TY  - JOUR
AU  - Genova, Carlo
AU  - Socinski, Mark A
AU  - Hozak, Rebecca R
AU  - Mi, Gu
AU  - Kurek, Raffael
AU  - Shahidi, Javad
AU  - Paz-Ares, Luis
AU  - Thatcher, Nick
AU  - Rivard, Christopher J
AU  - Varella-Garcia, Marileila
AU  - Hirsch, Fred R
PY  - 2017
DO  - 10.1016/j.jtho.2017.11.109
UR  - http://hdl.handle.net/10668/11824
T2  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
AB  - Necitumumab is a monoclonal antibody targeting EGFR. In the SQUIRE trial, the addition of necitumumab to chemotherapy for squamous cell lung cancer significantly improved overall survival (OS) (hazard ratio [HR] = 0.84); in a post hoc analysis, EGFR...
LA  - en
KW  - EGFR
KW  - FISH
KW  - Non–small cell lung cancer
KW  - biomarker
KW  - necitumumab
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Agents, Immunological
KW  - Carcinoma, Squamous Cell
KW  - Female
KW  - Gene Dosage
KW  - Humans
KW  - In Situ Hybridization, Fluorescence
KW  - Lung Neoplasms
KW  - Male
KW  - Treatment Outcome
TI  - EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study.
TY  - research article
VL  - 13
ER  -